title: Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates.
abstract: OBJECTIVE
  To study the effect of antiretroviral drugs administered during pregnancy on CD4 lymphocyte counts and HIV-1 RNA levels of pregnant women and on the anthropometric parameters of their neonates.
  
  
  METHODS
  A prospective study was conducted on 57 pregnant women and their neonates divided into 3 groups: ZDV Group, HIV-infected mothers taking zidovudine (n=20); triple therapy (TT) Group, mothers taking zidovudine+lamivudine+nelfinavir (n=25), and Control Group, normal women (n=12). CD4 lymphocyte counts and HIV-1 RNA levels of pregnant women were analyzed during two periods of pregnancy. The perinatal prognosis took into account preterm rates, birth weight, intrauterine growth restriction, perinatal death, and vertical transmission of HIV-1. Data were analyzed statistically using the nonparametric chi-square, Mann-Whitney, Friedman, Kruskal-Wallis, and Wilcoxon matched pairs tests, with the level of significance set at P<.05.
  
  
  RESULTS
  The major maternal demographic and anthropometric data were homogeneous for the various groups. HIV-1 viral burden, which was initially elevated, median of 14,370 copies/mL, was significantly reduced in the TT group, reaching 40 copies/mL. With respect to T-CD4+ lymphocyte counts, there was a significant recovery in Group TT at the end of pregnancy, this value being significantly different from that for the ZDV group (P=0052). There was no difference between groups regarding gestation length, Apgar scores, or neonatal anthropometric classification. There was no case of vertical HIV-1 transmission.
  
  
  CONCLUSIONS
  The results obtained for the present series demonstrate the efficiency and suggest safety of the use of antiretroviral drugs during pregnancy as revealed by anthropometric parameters of the neonate.
authors.affiliation: Department of Obstetrics and Gynecology, Medicine School of Ribeirão Preto, University of São Paulo, Brazil. pbeitune@ig.com.br
authors.forename: Patrícia
authors.initials: P
authors.lastname: El Beitune
authors.forename: Geraldo
authors.initials: G
authors.lastname: Duarte
authors.forename: Alcyone Artioli
authors.initials: AA
authors.lastname: Machado
authors.forename: Silvana Maria
authors.initials: SM
authors.lastname: Quintana
authors.forename: Ernesto A
authors.initials: EA
authors.lastname: Figueiró-Filho
authors.forename: Renata
authors.initials: R
authors.lastname: Abduch
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001724:Birth Weight / Q000187:drug effects*; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D019259:Lamivudine / Q000627:therapeutic use; D019888:Nelfinavir / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D019259:Lamivudine; D015215:Zidovudine; D019888:Nelfinavir